Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676173 | 1.00 | UTS2R (0.60) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5870780 | 1.00 | UTS2R (0.60) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30794394 | 1.00 | UTS2R (0.60) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5870868 | 0.89 | UTS2R (0.55) | UTS2RALDH1A1GPR88 | |
| SCHEMBL5870865 | 0.89 | UTS2R (0.55) | UTS2RALDH1A1GPR88 | |
| SCHEMBL5673117 | 0.89 | UTS2R (0.55) | UTS2RALDH1A1GPR88 | |
| SCHEMBL30795088 | 0.89 | UTS2R (0.55) | UTS2RALDH1A1GPR88 | |
| SCHEMBL5673084 | 0.89 | UTS2R (0.58) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL5673078 | 0.89 | UTS2R (0.58) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30794873 | 0.89 | UTS2R (0.58) | UTS2RALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045551-B2 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | claimed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-7045551-B2 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | KCNQ3, KCNQ2, KCNQ4 | UTS2R 2172/4885ALDH1A1 597/4885SMN1; SMN2 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.